Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced Pancreatic Adenocarcinoma

Model scores of the 29,894 trials active now.

Model score 27% for any early termination, 8% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 29% of the time (655 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2023-08-14. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: cancerrecurrentpaclitaxelsurgeryprostate
  Phrases that lowered it: open labellineefficacy andevaluate theto evaluate
• Sponsor's past termination rate: 50% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 1/2 (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Has a data monitoring committee: Yes (raises risk) · Design
• Design: single group (raises risk) · Design
• Drug's FAERS reports marked serious: 95.3% (raises risk) · Drug's FDA history
• Drug's FAERS reports with a death: 20.8% (lowers risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 3 (raises risk) · Sponsor's track record
• Number of arms: 3 (lowers risk) · Design
• Drug's FAERS reports in the prior 12 months: 12025 (lowers risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Maximum age: not given (raises risk) · Who can join
• Sponsor's past trials: 2 (lowers risk) · Sponsor's track record
• Blinding: none (raises risk) · Design
• Collaborators: 0 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer NCT03086369 · started 2017 · scored riskier than 79% of active trials completed
• Phase 2 Nab® -Paclitaxel (Abraxane®) Plus Gemcitabine in Subjects With Locally Advanced Pancreatic Cancer (LAPC) NCT02301143 · started 2015 · scored riskier than 93% of active trials completed
• Nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine For The First Line Treatment of Pancreas Cancer NCT03807999 · started 2015 · scored riskier than 52% of active trials completed
• Efficacy and Safety of Nab-Paclitaxel Plus S-1 in the First-line Treatment of Advanced Pancreatic Cancer NCT03415802 · started 2015 · scored riskier than 32% of active trials completed
• Study to Evaluate Bi-weekly Dosing of Gemcitabine Plus Nab-Paclitaxel to Treat Metastatic Pancreatic Cancer NCT01851174 · started 2013 · scored riskier than 93% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.